Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus METICORTELONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus METICORTELONE.
ASMANEX HFA vs METICORTELONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
Prednisolone: 5-60 mg orally once daily or divided twice daily; methylprednisolone: 4-48 mg orally once daily or divided twice daily. Dose and duration vary by indication.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life: 3.0-3.5 hours; clinical context: requires multiple daily doses for sustained effect; biological half-life (duration of HPA suppression) longer (~24-36 hours) due to intracellular activity
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal: <5% unchanged; hepatic metabolism to inactive metabolites, primarily conjugated and excreted in urine; <2% fecal
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid